Table 1.
Clinical data of study samples
| Tissue code | Localization | Stage | pTNM | Grading | Op | RTx | CTx | Disease‐free interval (weeks) | Overall survival (weeks) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CUP | IV | Tx N2b Mx | G2 | + | + | – | 164 | 164 |
| 2 | CUP | IV | Tx N3 Mx | G4 | + | + | – | 95 | 95 |
| 3 | CUP | IV | Tx N2 c Mx | G3 | + | + | – | 172 | 172 † |
| 4 | CUP | IV | Tx N2b Mx | G3 | + | + | – | 160 | 160 † |
| 5 | CUP | IV | Tx N2b Mx | G3 | + | + | – | 17 | 17 |
| 6 | CUP | IV | Tx N2a Mx | G3 | + | – | – | 3664 | 3664 † |
| 7 | CUP | III | Tx N1 Mx | G3 | + | + | – | 176 | 176 † |
| 8 | CUP | IV | Tx N2 c Mx | G4 | + | + | + | 96 | 224 |
| 9 | CUP | IV | Tx N2a M0 | G3 | + | + | – | 28 | 65 |
| 10 | CUP | IV | Tx N2b M0 | G3 | + | + | – | 48 | 48 |
| 11 | CUP | IV | Tx N2a Mx | G3 | + | + | – | 36 | 36 |
| 12 | Oropharynx | IV | T4 N0 M0 | G3 | + | + | + | 20 | 48 |
| 13 | Oropharynx | II | T2 N0 Mx | G2 | + | + | + | 58 | 58 |
| 14 | Oropharynx | IV | T4 N2 c M0 | G3 | + | + | + | 30 | 30 |
| 15 | Oropharynx | IV | T4 N2 c M0 | G3 | + | + | + | 12 | 68 |
| 16 | Oropharynx | III | T3 N1 M0 | G2 | + | + | – | 190 | 190 |
| 17 | Oropharynx | IV | T2 N2b M0 | G2–3 | + | + | + | 32 | 100 |
| 18 | Oropharynx | II | T2 N0 M0 | G3 | + | + | – | 33 | 64 |
| 19 | Oropharynx | IV | T4 N2b M0 | G3 | + | + | – | 28 | 48 |
| 20 | Oropharynx | IV | T1 N2b M0 | G3 | + | + | + | 240 | 240 † |
| 21 | Oropharynx | III | T3 N2b M0 | G2 | + | + | + | 72 | 140 |
| 22 | Larynx | IV | T4 N0 M0 | G2 | + | + | – | 264 | 264 † |
| 23 | Larynx | IV | T4 N0 M0 | G3 | + | + | – | 176 | 176 † |
| 24 | Larynx | IV | T4 N0 M0 | G3 | + | + | – | 156 | 156 † |
| 25 | Larynx | IV | T4 N2b M0 | G2 | + | + | + | 44 | 44 |
| 26 | Larynx | IV | T4 N2 c Mx | G3 | + | – | – | 57 | 57 |
| 27 | Larynx | IV | T4 N0 M0 | G2 | + | + | – | 304 | 304 † |
| 28 | Larynx | IV | T4 N0 M0 | G3 | + | + | – | 264 | 264 † |
| 29 | Larynx | III | T3 N1 M0 | G3 | + | + | – | 7 | 7 |
| 30 | Larynx | IV | T4 N2b M0 | G3 | + | + | + | 128 | 128 † |
| 31 | Larynx | IV | T4 N0 M0 | G3 | + | + | – | 32 | 32 |
| 32 | Hypopharynx | IV | T1 N2b M0 | G2 | + | + | – | 72 | 72 |
| 33 | Hypopharynx | III | T1 N1 M0 | G3 | + | + | + | 26 | 96 |
| 34 | Hypopharynx | IV | T2 N2 c M0 | G3 | + | + | – | 85 | 85 |
| 35 | Hypopharynx | IV | T3 N2 c M0 | G3 | + | + | – | 123 | 123 |
| 36 | Hypopharynx | IV | T4 N2 c M0 | G3 | + | + | + | 54 | 54 |
| 37 | Hypopharynx | IV | T4 N2b M0 | G3 | + | + | – | 54 | 54 |
| 38 | Hypopharynx | IV | T3 N2 c M0 | G3 | + | + | + | 36 | 100 |
| 39 | Hypopharynx | IV | T4 N2 c M0 | G3 | + | + | – | 40 | 40 |
| 40 | Hypopharynx | IV | T2 N2 c M0 | G3 | + | + | – | 60 | 63 |
| 41 | Hypopharynx | IV | T4 N2b M0 | G3 | + | + | – | 40 | 40 |
†
Indicates patients, still living at cut‐off date of evaluation; OP, radical surgery; RTx, radiotherapy (pts. 6 and 25 rejected RTx); CTx: chemotherapy concomitant with adjuvant RTx or in palliative setting; CUP, carcinoma of unknown primary.